Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars
ROCKVILLE, Md., Aug 24, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today hosted “Looking Beyond the Bench,” a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based on their extensive experience in the biopharmaceutical industry, [...]
In: Anthrax vaccines, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Research and development, Scholars Program · Tagged with: Anthrax vaccines, BioSolutions Inc, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Scholars Program
Maryland Governor Martin O’Malley Leads Ribbon Cutting Ceremony at Emergent’s Baltimore Manufacturing Facility
ROCKVILLE, MD, July 16, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon cutting ceremony, led by Governor Martin O’Malley and Fuad El-Hibri, Emergent’s chairman and chief executive officer, to mark the formal opening of Emergent Manufacturing Operations [...]
In: Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Health Care, Management, Research and development, U.S. Food and Drug Administration · Tagged with: Chief executive officer, Emergent BioSolutions, Employment, Fuad El-Hibri, Martin O'Malley, Maryland, United States
Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland
ROCKVILLE, MD, May 13, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland’s (TCM) Annual Tech Awards. This award acknowledges the company that best exemplifies the spirit of Maryland’s biotechnology community as well as its presence and leadership within the [...]
In: Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Research and development, Tech Council of Maryland, U.S. Food and Drug Administration · Tagged with: Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Research and development, Tech Council of Maryland
Emergent BioSolutions Hosts Biopreparedness Forum for Members of the NATO Parliamentary Assembly
Emergent BioSolutions’ senior management team, headed by Fuad El-Hibri, chairman and chief executive officer and Daniel J. Abdun-Nabi, president and chief operating officer, are hosting “Bioterrorism Prevention, Preparedness and Response,” a forum uniquely organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA). The one-day event is an interactive discussion related to [...]
In: Emergent BioSolutions, Hudson Institute, NATO, North Atlantic Treaty Organization, United States Department of Defense · Tagged with: Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Hudson Institute, NATO, North Atlantic Treaty Organization, United States, United States Department of Defense
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader
ROCKVILLE, Md., Mar 11, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (EBS 15.96, -0.03, -0.19%) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been named by the World Trade Center Institute (WTCI) as one of Maryland’s outstanding international business leaders. Celebrating the spirit of global ambition and excellence in international leadership, [...]
In: Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Management, U.S. Food and Drug Administration, biotechnology · Tagged with: Baltimore, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Maryland
Emergent BioSolutions reacts to BARDA’s Request for Proposal cancellation
by Nick Rees on December 8, 2009
Fuad El-Hibri
The Office of the Biomedical Advanced Research and Development Authority has advised Emergent BioSolutions that while BARDA’s Request for Proposal has been canceled, Emergent is encouraged to submit a proposal for the office’s Broad Agency Announcement.
BARDA canceled the RFP for the procurement for rPA vaccines after [...]
In: Biothrax, Business, CEO, Crisis, Emergent BioSolutions, Fuad El-Hibri, Management, U.S. Food and Drug Administration · Tagged with: Chief executive officer, El-Hibri, Emergent BioSolutions, Fuad El-Hibri, Public health, United States Department of Health and Human Services
Emergent BioSolutions reacts to BARDA’s Request for Proposal cancellation
by Nick Rees on December 8, 2009
Fuad El-Hibri
The Office of the Biomedical Advanced Research and Development Authority has advised Emergent BioSolutions that while BARDA’s Request for Proposal has been canceled, Emergent is encouraged to submit a proposal for the office’s Broad Agency Announcement.
BARDA canceled the RFP for the procurement for rPA vaccines after [...]
In: Board of directors, Chief executive officer, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Leadership, Shareholders, U.S. Department Of Health And Human Services, biotechnology · Tagged with: Biotechnology and Pharmaceuticals, Chief executive officer, Emergent BioSolutions, U.S. Food and Drug Administration
Emergent BioSolutions Enhances Manufacturing Infrastructure with Strategic Acquisition in Baltimore
Emergent acquires manufacturing facility from MdBio and land from City of Baltimore for $8.2 million
ROCKVILLE, MD, November 13, 2009 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore [...]
In: Fuad El-Hibri · Tagged with: Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Martin O'Malley, Maryland, State of Maryland, United States
Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript
Emergent BioSolutions Inc., (EBS)
Q2 2009 Earnings Call
August 6, 2009 5:00 pm ET
Executives
Robert G. Burrows – Vice President, Investor Relations
Fuad El-Hibri – Chairman of the Board, Chief Executive Officer
R. Don Elsey – Chief Financial Officer
Daniel J. Abdun-Nabi – President, Chief Operating Officer
W. James Jackson, Ph.D. – Senior Vice President and Chief Scientific Officer
Analysts
Eric Schmidt [...]
In: Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Shareholders, U.S. Food and Drug Administration · Tagged with: Business, Chairman, Chief executive officer, Chief financial officer, Chief operating officer, finance, Investor relations, Vice president
STATEMENT BY FUAD EL-HIBRI, EMERGENT BIOSOLUTIONS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ON THE PASSING OF ADMIRAL WILLIAM CROWE, JR., FORMER BOARD MEMBER.
ROCKVILLE, MD, October 19, 2007— Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, issued the following statement on the passing of Admiral William Crowe, Jr., who served on the company’s Board of Directors from 1998-2005.
“I was deeply saddened to learn of the passing of my dear friend and former colleague, the honorable Admiral [...]
In: Biothrax, Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri · Tagged with: Anthrax vaccines, Board of directors, Chief executive officer, Emergent BioSolutions, Health, Infectious disease, U.S. Food and Drug Administration, United States
